PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma

NCT06322927 | Completed DMC

• 2 other identifiers: CFTsp23124_CPCR_38
• Study Type: observational
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.

Conditions

Multiple Myeloma

Keywords

Patient Experience; Treatment Preference; Qualitative Study; Patient Interviews

Outcome Measures

Primary Outcomes (1)

• Patient Experience and Preference

  The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.

  30-60 minutes

Secondary Outcomes (1)

• Treatment and Preference Differences

  30-60 minutes

Study Arms (1)

Patient Interviews

Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference.

Other: Patient Interview

Interventions

Patient Interview OTHER

Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.

Patient Interviews

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with multiple myeloma who have received at least five lines of treatment.

You may qualify if:

• Participants with confirmed MM (per standard disease specific diagnostic criteria)
• Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:
• Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment.
• Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy.
• Aged 18 years of age or over
• Able to provide informed consent
• Able to communicate in English

You may not qualify if:

• Aged under 18
• Unable to understand and communicate in the English language
• Unable to provide written informed consent

Sponsors & Collaborators

• The Christie NHS Foundation Trust: lead
• CellCentric Ltd.: collaborator

Study Sites (1)

The Christie NHS Foundation Trust

Manchester, Greater Manchester, M20 4BX, United Kingdom

Location

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Sally Taylor, PhD

  The Christie NHS Foundation Trust

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 14, 2024
• First Posted: March 21, 2024
• Study Start: April 5, 2024
• Primary Completion: September 30, 2024
• Study Completion: September 30, 2024
• Last Updated: December 4, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)